Clinical Trial

A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B

Name: A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B — clinical trial record (NCT07203118)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research.

Trial Details

NCT Number	NCT07203118
Lead Sponsor	Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Conditions	Chronic Hepatitis B
Enrollment	1,444 participants
Start Date	2025-07-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2030-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-10-02